Drugs / Cytoflavin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05935787 | Jun 2023 → Jun 2024 | stroke disorder | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | No outcome recorded |
| Phase 3 | NCT04649203 | Nov 2020 → Mar 2021 | diabetic polyneuropathy | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | Met primary |
| Phase 3 | NCT03849664 | Jun 2017 → Apr 2019 | cognitive disorder | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytoflavin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04649203 ↗ |
| Route | Intravenous | “will be administered IV for 7 days” NCT03849664 ↗ |